The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma.

Br J Dermatol. 1999 May;140(5):875-81. Unique Identifier : AIDSLINE MED/99282216
Dupin N; Rubin De Cervens V; Gorin I; Calvez V; Pessis E; Grandadam M; Rabian C; Viard JP; Huraux JM; Escande JP; Service de Dermato-Venereologie, Hopital Tarnier-Cochin,; Paris, France; Laboratoire de Virologie, Groupe Hospitalier; Pitie-Salpetriere, Paris, France. nicolas@icr.ac.uk

Abstract: To assess the clinical and biological benefit of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma (KS), 13 patients with AIDS-associated Kaposi's sarcoma (five pulmonary KS and eight cutaneous KS) were prospectively followed for a mean duration of 12 months. Six patients were treated with specific anti-KS chemotherapy before or simultaneously with the introduction of antiretroviral therapy. Clinical response was assessed according to the AIDS Clinical Trial Group (ACTG) criteria. CD4 cell counts, plasma HIV-1 RNA and human herpesvirus 8 (HHV-8) viraemia were measured at baseline and at different points. Among patients with pulmonary KS, we observed three complete responses (CR), one partial response (PR) and one progression. The median survival time after the diagnosis of pulmonary KS was 15 months with a median duration of the response after the discontinuation of specific chemotherapy for KS of 8 months. Among patients with cutaneous KS, we observed four CR, three PR and one stable response. A complete response was significantly associated with a reversal in HHV-8 viraemia (five of six vs. one of six; P = 0.02, Mann-Whitney test).

Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/*COMPLICATIONS/DRUG THERAPY/ IMMUNOLOGY Adult CD4 Lymphocyte Count Drug Therapy, Combination Herpesvirus, Kaposi Sarcoma-Associated/ISOLATION & PURIF Human HIV Protease Inhibitors/*THERAPEUTIC USE *HIV-1/GENETICS Lung Neoplasms/COMPLICATIONS/*DRUG THERAPY/IMMUNOLOGY Male Middle Age Prospective Studies RNA, Viral/BLOOD Sarcoma, Kaposi/COMPLICATIONS/*DRUG THERAPY/IMMUNOLOGY Skin Neoplasms/COMPLICATIONS/*DRUG THERAPY/IMMUNOLOGY Statistics, Nonparametric Support, Non-U.S. Gov't Survival Rate Treatment Outcome Viremia/COMPLICATIONS/DRUG THERAPY
000730
A0071489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .